1 / 48

ALLOGRAFT VALVE SURGERY

ALLOGRAFT VALVE SURGERY. P.Skillington CANBERRA April 2003. Aortic Valve Replacement. Aetiology of Valvular Disease Pathology encountered Operations Available: focus on Allograft Operative Techniques Results. Aortic Valve - Aetiology.

obelia
Download Presentation

ALLOGRAFT VALVE SURGERY

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ALLOGRAFT VALVE SURGERY P.Skillington CANBERRA April 2003

  2. Aortic Valve Replacement • Aetiology of Valvular Disease • Pathology encountered • Operations Available: focus on Allograft • Operative Techniques • Results

  3. Aortic Valve - Aetiology • Congenital: bicuspid, monocuspid age – 0-70 (peak 35-50) • Degenerative: tricuspid age - >60 (peak 70-80) • Rheumatic: Post rheumatic fever, uncommon in Australia age – all ages

  4. AVR: Choice of Prosthesis • Durability of Prosthesis • Necessity for Warfarin- temporary or permanent • Risk of Thrombo-embolism & Bleeding • Re-operation rate & difficulty

  5. Patient Related Factors • Haemodynamic Performance: flow dynamics functional state achieved • Biocompatibility • Effect of various disease states eg: Marfans,other connective tissue diseases • Possible future pregnancy • Valve noise

  6. Excellent Durability 95% at 10yrs. 90% at 20yrs Low rate of re-operation. Easy to insert Warfarin, blood tests Thrombo-embolism 1-2%/pt/yr Bleeding risk 2%/pt/yr Non Cardiac Surgery hazardous Do not need warfarin Low risk of thrombo-embolism and bleeding : 0-1% Noiseless Durability variable:ie higher rate of re-operation Insertion may be more difficult Other surgery safe AVR : Mechanical vs. Tissue Valve

  7. Tissue Valve Durability • Porcine,Pericardial: 40yrs:– 8-10 yrs 70yrs:- 12-15yrs • Aortic Allograft: 20yrs:- 10yrs 40-70yrs:- 15yrs • Ross Procedure: On average,will last 40-50yrs (variable) Re-operation rate:- 1%/pt/yr

  8. Stentless Porcine ValveAVR in elderlyBetter Haemodynamic functionLarger orifice areaBetter resolution of Left Ventricular Hypertrophy

  9. Aortic Allograft Insertion • Human cadaveric Ao. v • Cryopreserved • AVR • Root Replacement vs Subcoronary

  10. Aortic Homograft (Allograft) • Durability • Better than Xenografts eg 50yr old: expect 15yr lifespan (vs 10 yrs ) • OtherAdvantages • Endocarditis with aortic root abcess • Warfarin not required Disadvantages • Not on shelf • Re-operation difficult

  11. M.O’Brien et al “The Homograft Aortic Valve:29 yrs” J. Heart V. Dis 2001;10:334-345 1,022 patients mean age 47yrs: Actuarial Survival

  12. O’Brien et al,2001 Aortic Homograft Durability vs Age: Freedom from Re-op

  13. Summary – Allograft AVR • Best age range: 30 – 65 yrs • Durability in that age range: 15yrs avge • Indications: Endocarditis Not suitable for Ross Proc. • Results: 78 pts over 12 yrs (1990-2002) Early Mortality: 0 Late re-operation: 3

  14. Ross Procedure • Advantages • Viable aortic valve • Improved Durability cf other tissue valves • No Warfarin absence T/E, ARH • Disadvantages • Longer operation • Follow up of pulmonary valve

  15. Ross Procedure • Indications • Age 20-60yrs, requiring AVR • Contra-indications • Bicuspid pulmonary valve(echo) • Marfans Syndrome • Other connective tissue disease R.arthritis/ SLE • Active rheumatic heart disease • Triple vessel CAD/ Mitral v. dis.

  16. Patient Demographics (Ross P.) Time Frame : October 1992 to February 2003 No. of Patients : 172 1. Age: Range 16-62 (Mean 39.3) 2. :Gender M = 122 (70.9%) F = 50 (29.1%) 3. Valve Lesion: Aortic Stenosis: 68 (40%) AS/AR(Mixed): 51 (29%) Aortic Regurg: 53 (31%) 4. Aortic Valve Aetiology: Congenital: 158 (92%) Other: 14 (8%) 5. Re-operation: 19 (11%)

  17. Microsoft Excel Spreadsheet – May 2002

  18. MORTALITY & MORBIDITY N=172 1. Early Mortality (in hosp. Or within 30 days) 1 (0.6%) Myocardial Infarct 2. Early Morbidity - Re-Exploration 9 (a) Bleeding 7 (4.1%) (b) Graft RCA. 1 ( c ) Low C.O. 1 - Retinal Embolus 1 - CHB >>> Pacemaker 1 - Renal Impairment 4 - AMI 2 - Inotropes 3 - IABP 1 - Respiratory Failure (Re-Intubation) 1 - Pericardial Effusion 1 - Arrhythmia Ventricular 2 Atrial (AF) 20 -Sternal Infection 1

  19. Late Results (n = 172) Late Death (non-cardiac) 2 1.2% • Follow up 98.6% complete 735 patient years • Thrombo-embolism 1 Cumulative Inc. 0.1% • Bleeding(ARH) 0 0.0% • Endocarditis 0 0.0% • Re-operation 6 0.8% • Late AR>mild 0 0.0% * 5yr freedom from re-operation = 96.2%

  20. Ross (inclusion cylinder) Actuarial Survival: 155 patients 5yrs = 98% 7yrs = 95% 155 127 101 83 54 37 19 7 4

  21. (n=155) 5yrs = 99% 7yrs = 99% 155 127 101 83 54 37 19 7

  22. Zellner et al “Long term experience With the St.Jude Medical Valve Prosthesis” South Carolina,USA AVR 418 pts, mean age 54.8yrs Re-operation inc. 1.0%/pt/y *10yr survival 58%

  23. Pregnancy after the Ross Procedure • Seven women have under gone 11 successful pregnancies • No maternal cardiac complications • No problems with the passengers • Favourable in contrast with mechanical valves

  24. Durability Aortic Valve Prostheses

  25. Pulmonary Regurgitation

  26. AVR - Choice Prosthesis-Effect of Age • 15-60 yrs • Ross, Mechanical, Allograft • 60-70 yrs • Mechanical, Allograft, Porcine/Pericardial • >70 yrs • Stentless Porcine,Stented Pericardial, Mechanical

  27. Results Pulmonary Allograft Insertion for Tetralogy, other Congenital Cardiac • 45 patients over 12 year period • zero mortality, minimal complications • Beating heart surgery • Do not require warfarin • Quality of life very good

  28. Conclusion • 300 patients have had cardiac allograft valve replacement: Ross Procedure 177 Aortic Allograft 78 Pulmonary Allograft 45 • Safe surgery: one(1) early death • Excellent quality of life without anti- coagulants : young people

  29. Standard Post-op Management Early BP(sys, mean) ; filling pressures (R+L) C. Output – depends on temperature Low CO (>37 C) Pericardial Tamponade signs of tamponade : low bp,high cvp,low urine output (usually prior bleeding) Improve CO optimal filling (+ve balance 1-2 l) vasodilators (GTN, prop., nipride) inotropes (milrinone, NOT adr,dop) noradrenaline IABP rate(80-90),rhythm

  30. ANTICOAGULATION • AVR mechanical : INR, Time to reach 2.0 pacing wire removal day 3-4 if not required porcine / pericardial : warfarin 6 weeks Ross / Allograft : aspirin 3months • MVR mechanical INR 3.0 ,if chr.AF, clexane after 3-4 days porcine / pericardial Warfarin at least 3 months, often permanent • MV Repair Warfarin 3 months

  31. Special Situations • Mitral valve surgery /PHT : pul vaso-dil ,extub, sw ganz, LA line ,b. gases, pht crisis • AVR for AS and severe LVH • AVR thin walled aorta – sys BP • Ross : Sw Ganz removal • Patients with poor LV sys function :early IABP • TVR : pacing , cvp only for Repl. • PVR : Usually no PA catheter

  32. Stentless Tissue Valves • Examples include: stentless porcine valve Aortic Allograft (homograft) Ross Proc. (pul.autograft) • Features: Better haemodynamic funct. Improved resolution of left ventricular hypertrophy

  33. Haemodynamic Function Residual aortic valve gradient(mmHg) • Ross (pulmonary autograft) 2-4 • Stentless Porcine 5 • Aortic Allograft 6 • Mechanical 10-20 • Stented Porcine/Pericardial 12-25 *gradients at rest

  34. MITRAL VALVE - Aetiology • Myxoid Degeneration – 75% Repair • Rheumatic – 95% Replacement • Ischaemic – 50% Repair, 50% Replace • Other – Endocarditis, SLE, Chordal Rupture

  35. Actuarial Survival 5yr. 97.5% 5yr.Cardiac Related 98.7% 5 5 yr. 132 107 86 65 41 22 No.Patients

  36. AVR - Mortality • Depends on age ,cor.dis.,LV function <70 1% 70-80 2% >80 3-5%

  37. Conclusions • Early Mortality for AVR very low – all ages • Tissue Valves favoured where possible,especially in the elderly,to avoid warfarin related problems & T- embolism • If Tissue Valve used, Stentless valve is better haemodynamically • In the elderly, patient will usually outlive their valve • In younger patients, Ross Proc. is safe, good quality of life, low risk re-operation

  38. ALREADY SHOWN • Low Operative Mortality and Morbidity • Resolution LVH • Normalization LV Size and Function AIMS • Late Valve Related Events • Aortic Valve Function and Need For Re-Operation

  39. AORTIC VALVE FAILURE • A.R. Re-operation • Moderate Aortic Regurgitation or Greater Factors Analyzed • Age • Sex • Aortic Valve Lesion : AS/AR/Mixed • Aortic Annulus Diameter • Aortic Annulus Reduction • Method Implantation of Autograft

  40. TORONTO SPVCLINICAL SERIES June 1994 – May 2001 90 Patients Mean Age 75.5 years (61-87) Sex : Male 53.3% (48) Female 46.7% (42)

  41. Results Stentless Valve Insertion Early MortalityRe-operation Hospital <30 days Total (%/pt/yr) Ross Proc. 143 0 1 1(0.7%) 0.9 TSPV 90 1 1 2(2.2%) 0 Aortic Allo. 35 0 0 0 1.5

  42. Aortic Allograft :- Indications • Endocarditis : Lowest risk of recurrent infection Exclusion of abcess cavities • Women of child bearing age • <60 yrs:-Unsuitable for Ross Procedure • 60-70yrs:-Unsuitable for Mechanical device

  43. Cardiac Surgery • Modern Surgical specialty • 1953: Development of the heart/lung machine (cardiopulmonary bypass) allowed intracardiac procedures to be performed on the empty heart • Later improvements (cardioplegia) led to Asystolic arrest– flaccid or still heart • 1960: Cardiac Valve Replacement • 1968: Coronary Artery Bypass Surgery

More Related